Skip to main content
SpringerLink
Log in

Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia

  • Chapter
  • First Online:
Chronic Lymphocytic Leukemia

Part of the book series: Hematologic Malignancies ((HEMATOLOGIC))

Abstract

The management of patients with relapsed or refractory chronic lymphocytic leukemia (CLL) has undergone significant changes during the last decade. As with first-line treatment, the treatment choice of relapsed CLL patients is dependent on several factors, including age, performance status, comorbidities, and duration of response to previous therapy. The outcome of second, and subsequent, lines of therapy is markedly improved by the addition of CD20-antibodies to established chemotherapeutic regimen, inhibitors of B-cell receptor (BCR), or B-cell lymphoma 2 (BCL-2) antagonists. Large randomized trials have confirmed that chemoimmunotherapy with fludarabine and cyclophosphamide (FC) with rituximab (FCR) or ofatumumab (OFC) in fit relapsed/refractory patients is more effective than FC alone. Bendamustine and a bendamustine/rituximab combination have also shown high efficacy in patients with relapsed/refractory CLL, who have received prior therapy with other alkylating agents or purine analogs. Patients with the presence of del(17p) and/or TP53 mutations should be treated with the BCR signaling inhibitors, ibrutinib or idelalisib. Other patients poorly responding to chemoimmunotherapy in previous lines also require treatment with BCR inhibitors. Patients who do not respond to BCR inhibitors, or do not tolerate them, are candidates for the BCL-2 antagonist venetoclax or other investigational drugs currently in clinical trials. Physically fit patients with refractory CLL or with a del(17p) should be considered for allogeneic hematopoietic stem cell transplantation. Participation in clinical trials of novel agents should be strongly recommended for all refractory patients.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hallek M, Cheson B, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood. 2008;111:5446–56.

    Article  CAS  Google Scholar 

  2. Zenz T, Gribben JG, Hallek M, et al. Risk categories and refractory CLL in the era of chemoimmunotherapy. Blood. 2012;119:4101–7.

    Article  CAS  Google Scholar 

  3. Ahn IE, Farber CM, Davids M, et al. Early progression of disease (<2 years) is a negative predictor of survival in patients (Pts) with chronic lymphocytic leukemia (CLL): an analysis from the Connect® CLL registry. Blood. 2016;128:3581.

    Article  Google Scholar 

  4. Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.

    Article  CAS  Google Scholar 

  5. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.

    Article  Google Scholar 

  6. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.

    Article  CAS  Google Scholar 

  7. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–78.

    Article  CAS  Google Scholar 

  8. Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:311–22.

    Article  CAS  Google Scholar 

  9. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v78–84.

    Article  Google Scholar 

  10. Cramer P, Isfort S, Bahlo J, et al. Outcome of advanced chronic lymphocytic leukemia following different first-line and relapse therapies: a meta-analysis of five prospective trials by the German CLL Study Group (GCLLSG). Haematologica. 2015;100:1451–9.

    Article  CAS  Google Scholar 

  11. Robak T, Blonski JZ, Kasznicki M, Gora-Tybor J, Dmoszynska A, Skotnicki A. The effect of subsequent therapies in patients with chronic lymphocytic leukemia previously treated with prednisone and either cladribine or chlorambucil. Haematologica. 2005;90:994–6.

    CAS  PubMed  Google Scholar 

  12. Fornecker LM, Aurran-Schleinitz T, Michallet AS, et al. Salvage outcomes in patients with first relapse after fludarabine, cyclophosphamide, and rituximab for chronic lymphocytic leukemia: the French intergroup experience. Am J Hematol. 2015;90:511–4.

    Article  CAS  Google Scholar 

  13. Dlouhy I, Ghita G, Baumann T, et al. Retreatment with purine analogs in patients with chronic lymphocytic leukemia. Leuk Res. 2012;36:1521–5.

    Article  CAS  Google Scholar 

  14. Weide R, Feiten S, Friesenhahn V, et al. Retreatment with bendamustine-containing regimens in patients with relapsed/refractory chronic lymphocytic leukemia and indolent B-cell lymphomas achieves high response rates and some long lasting remissions. Leuk Lymphoma. 2013;54:1640–6.

    Article  CAS  Google Scholar 

  15. Robak T, Dmoszynska A, Solal-Céligny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1756–65.

    Article  CAS  Google Scholar 

  16. Robak T, Warzocha K, GovindBabu K, et al. Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial. Leuk Lymphoma. 2017;58:1084–93.

    Article  CAS  Google Scholar 

  17. Awan FT, Hillmen P, Hellmann A, et al. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2014;167:466–77.

    Article  CAS  Google Scholar 

  18. Elter T, Gercheva-Kyuchukova L, Pylylpenko H, et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. 2011;12:1204–13.

    Article  CAS  Google Scholar 

  19. Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200–11.

    Article  CAS  Google Scholar 

  20. Jones JA, Robak T, Brown JR, et al. Results of a phase 3 randomised, controlled study evaluating the efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia. Lancet Hematol. 2017;4:e114–26.

    Article  Google Scholar 

  21. Jones JA, Wach M, Robak T, et al. Results of a phase III randomized, controlled study evaluating the efficacy and safety of idelalisib (IDELA) in combination with ofatumumab (OFA) for previously treated chronic lymphocytic leukemia (CLL). J Clin Oncol. 2015;33(Suppl):7023.

    Article  Google Scholar 

  22. Zelenetz AD, Barrientos J, Brown JR, et al. Idelalisib with bendamustine and rituximab in relapsed chronic lymphocytic leukemia. Lancet Oncol. 2017;18:297–311.

    Article  CAS  Google Scholar 

  23. Zelenetz AD, Brown JR, Delgado J, et al. Updated analysis of overall survival in randomized phase III study of idelalisib in combination with bendamustine and rituximab in patients with relapsed/refractory CLL. Blood. 2016;128:231.

    Google Scholar 

  24. Bosch F, Abrisqueta P, Villamor N, et al. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. J Clin Oncol. 2009;27:4578–84.

    Article  CAS  Google Scholar 

  25. Faderl S, Wierda W, O’Brien S, et al. Fludarabine, cyclophosphamide, mitoxantrone plus rituximab (FCM-R) in frontline CLL <70 years. Leuk Res. 2010;34:284–8.

    Article  CAS  Google Scholar 

  26. Mato AR, Nabhan C, Barr PM, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128:2199–205.

    Article  CAS  Google Scholar 

  27. Bergmann MA, Goebeler ME, Herold M, et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica. 2005;90:1357–64.

    CAS  PubMed  Google Scholar 

  28. Lissitchkov T, Arnaudov G, Peytchev D, Merkle K. Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol. 2006;132:99–104.

    Article  CAS  Google Scholar 

  29. Fischer K, Cramer P, Busch R, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase 2 trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2011;29:3559–66.

    Article  CAS  Google Scholar 

  30. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28:1749–55.

    Article  CAS  Google Scholar 

  31. Österborg A, Jewell RC, Padmanabhan-Iyer S, et al. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study. Haematologica. 2015;100:e311–4.

    PubMed  PubMed Central  Google Scholar 

  32. Cortelezzi A, Sciume M, Liberati AM, et al. Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. Leukemia. 2014;28:642–8.

    Article  CAS  Google Scholar 

  33. Cartron G, de Guibert S, Dilhuydy M-S, et al. Obinutuzumab (GA101) in relapsed/refractory chronic lymphocytic leukemia: final data from the phase 1/2 GAUGUIN study. Blood. 2014;124:2196–202.

    Article  CAS  Google Scholar 

  34. Keating M, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (CAMPATH-1H) in patients who have failed fludarabine: results of a large international study. Blood. 2002;99:3554–61.

    Article  CAS  Google Scholar 

  35. Stilgenbauer S, Zenz T, Winkler D, et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009;l27:3994–4001.

    Article  Google Scholar 

  36. Elter T, Borchmann P, Schulz H, et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol. 2005;23:7024–31.

    Article  CAS  Google Scholar 

  37. Castro JE, Sandoval-Sus JD, Bole J, et al. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocyticleukemia. Leukemia. 2008;22:2048–53.

    Article  CAS  Google Scholar 

  38. Bowen DA, Call TG, Jenkins GD, et al. Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features. Leuk Lymphoma. 2007;48:2412–7.

    Article  CAS  Google Scholar 

  39. Dungarwalla M, Evans SO, Riley U, et al. High dose methylprednisolone and rituximab is an effective therapy in advanced refractory chronic lymphocytic leukemia resistant to fludarabine therapy. Haematologica. 2008;93:475–6.

    Article  Google Scholar 

  40. Burger JA, Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia. Trends Immunol. 2013;34:592–601.

    Article  CAS  Google Scholar 

  41. Robak P, Robak T. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia. Curr Med Chem. 2012;19:5294–318.

    Article  CAS  Google Scholar 

  42. Maffei R, Fiorcari S, Martinelli S, et al. Targeting neoplastic B cells and harnessing microenvironment: the “double face” of ibrutinib and idelalisib. J Hematol Oncol. 2015;8:60.

    Article  Google Scholar 

  43. Sanford DS, Wierda WG, Burger JA, et al. Three newly approved drugs for chronic lymphocytic leukemia: incorporating ibrutinib, idelalisib, and obinutuzumab into clinical practice. Clin Lymphoma Myeloma Leuk. 2015;15:385–91.

    Article  Google Scholar 

  44. O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–18.

    Article  Google Scholar 

  45. Brown JR, Barrientos JC, Barr PM, et al. The Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125:2915–22.

    Article  CAS  Google Scholar 

  46. Burger JA, Keating MJ, Wierda WG, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol. 2014;15:1090–9.

    Article  CAS  Google Scholar 

  47. Robak T. Ibrutinib in chronic lymphocytic leukaemia: alone or in combination? Lancet Oncol. 2016;17:129–31.

    Article  Google Scholar 

  48. Dreger P, Michallet M, Hoek J, et al. Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: first results of a survey by the Chronic Malignancy and the Lymphoma Working Parties of the EBMT. Blood. 2016;128:4657.

    Google Scholar 

  49. Link CS, Teipel R, Heidenreich F, et al. Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51:793–8.

    Article  CAS  Google Scholar 

  50. Ryan CE, Sahaf B, Logan AC, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128:2899–908.

    Article  CAS  Google Scholar 

  51. Brown JR, Byrd JC, Coutre SE, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood. 2014;123:3390–7.

    Article  CAS  Google Scholar 

  52. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–7.

    Article  Google Scholar 

  53. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia (CLL) after discontinuing ibrutinib. Blood. 2015;125:2062–7.

    Article  CAS  Google Scholar 

  54. Majid A, Tsoulakis O, Walewska R, et al. BCL2 expression in chronic lymphocytic leukemia: lack of association with the BCL2 938A>C promoter single nucleotide polymorphism. Blood. 2008;111:874–7.

    Article  CAS  Google Scholar 

  55. Jones J, Choi MY, Mato AR, et al. Venetoclax (VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to ibrutinib or idelalisib. Blood. 2016;128:637.

    Google Scholar 

  56. Seymour JF, Davids MS, Roberts AW, et al. Safety profile of venetoclax monotherapy in patients with chronic lymphocytic leukemia. Blood. 2016;128:4395.

    Google Scholar 

  57. Brander D, Roberts AW, Seymour JF, et al. Durable treatment-free remission and effective retreatment in patients with relapsed/refractory chronic lymphocytic leukemia who achieved a deep response with venetoclax combined with rituximab. Haematologica Abstract: P223. 2016.

    Google Scholar 

  58. Mato AR, Hil BT, Lamann N, et al. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in CLL: results from a large multi-center study of 683 US-patients. Blood. 2016;128:4400.

    Article  Google Scholar 

  59. Byrd JC, Harrington B, O’Brien S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374:323–32.

    Article  CAS  Google Scholar 

  60. Brown JR, Harb WA, Hill BT, et al. Phase 1 study of single agent CC-292, a highly selective Bruton’s tyrosine kinase (BTK) inhibitor, in relapsed/refractory chronic lymphocytic leukemia (CLL). Blood. 2013;122:1630.

    Google Scholar 

  61. Coutré SE, Barrientos JC, Brown JR, et al. Management of adverse events associated with idelalisib treatment: expert panel opinion. Leuk Lymphoma. 2015;56:2779–86.

    Article  Google Scholar 

  62. Kater AP, Tonino SH, Kersten MJ, et al. Interim analysis of dose-escalation stage of a phase 1b study evaluating safety and pharmacology of GS-9820, a second-generation, selective, PI3Kd-inhibitor in recurrent lymphoid malignancies. Blood. 2013;122:2881.

    Google Scholar 

  63. O’Connor OA, Flinn IW, Patel MR, et al. TGR-1202, a novel once daily PI3K-delta inhibitor, demonstrates clinical activity with a favorable safety profile in patients with CLL and B-cell lymphoma. Blood. 2015;126:4154.

    Google Scholar 

  64. Chen SS, Ham S, Rai KR, et al. Dual inhibition of PI3K-delta and gamma by duvelisib (IPI-145) impairs CLL B- and T-cell migration, survival and proliferation in a murine xenograft model using primary chronic lymphocytic leukemia cells. Blood. 2015;126:1753.

    Article  Google Scholar 

  65. Sharman JP, Farber CM, Mahadevan D, et al. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukaemia: results of a phase 2 trial. Br J Haematol. 2017;176:412–20.

    Article  CAS  Google Scholar 

  66. Robak T, Hellmann A, Kloczko J, et al. Randomized phase 2 study of otlertuzumab and bendamustine versus bendamustine in patients with relapsed chronic lymphocytic leukaemia. Br J Haematol. 2017;176:618–28.

    Article  CAS  Google Scholar 

  67. Ding W, Le-Rademacher J, Call TG, et al. PD-1 blockade with pembrolizumab in relapsed CLL including Richter’s transformation: an updated report from a phase 2 trial (MC1485). Blood. 2016;128:4392.

    Google Scholar 

  68. Jain N, Basu S, Thompson PA, et al. Nivolumab combined with ibrutinib for CLL and Richter transformation: a phase II trial. Blood. 2016;128:59.

    Article  Google Scholar 

  69. Krämer I, Stilgenbauer S, Dietrich S, et al. Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2016;128:682.

    Google Scholar 

  70. Dreger P, Corradini P, Kimby E, et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia. 2007;21:12–7.

    Article  CAS  Google Scholar 

  71. Kharfan-Dabaja MA, Kumar A, Hamadani M, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2016;22:2117–25.

    Article  Google Scholar 

  72. Robak T, Stilgenbauer S, Tedeschi A. Front-line treatment of CLL in the era of novel agents. Cancer Treat Rev. 2017;53:70–8.

    Article  CAS  Google Scholar 

Download references

Acknowledgement

We thank Edward Lowczowski from the Medical University of Lodz, for editorial assistance.

This work was supported in part by the grant from the Medical University of Lodz, Poland (No 503/1-093-01/503-11-001).

Author information

Authors and Affiliations

  1. Department of Hematology, Medical University of Lodz, Lodz, Poland

    Tadeusz Robak

Authors
  1. Tadeusz Robak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tadeusz Robak .

Editor information

Editors and Affiliations

  1. Department I of Internal Medicine, University of Cologne, Cologne, Nordrhein-Westfalen, Germany

    Michael Hallek

  2. Department I of Internal Medicine, University of Cologne, Cologne, Nordrhein-Westfalen, Germany

    Barbara Eichhorst

  3. Division of Molecular Pathology, The Institute of Cancer Research, London, UK

    Daniel Catovsky

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Robak, T. (2019). Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia. In: Hallek, M., Eichhorst, B., Catovsky, D. (eds) Chronic Lymphocytic Leukemia. Hematologic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-030-11392-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-11392-6_8

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-11391-9

  • Online ISBN: 978-3-030-11392-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation